Targeted therapy in hormone refractory prostate cancer
Targeted therapy in hormone refractory prostate cancer
复制标题
DOI：
10.1007/s11523-007-0063-4
复制
发表时间：
2007-10
影响因子：
5.4
通讯作者：
S. Burbridge;Simon Chowdhury;Peter Harper
中科院分区：
文献类型：
--
作者：
S. Burbridge;Simon Chowdhury;Peter Harper
尽管最近在激素难治性前列腺癌的治疗方面取得了进展，多西他赛化疗具有生存优势，但在这一重要患者群体中仍需要进一步改善。新的靶向药物有希望作为单一药物，并与化疗联合。然而，需要进一步的工作，以确定治疗目标，并开发活性剂，以期将其引入标准的临床实践。
Despite recent progress in the treatment of hormone refractory prostate cancer—with a survival advantage seen with docetaxel chemotherapy—there remains a need for further improvements in this important patient group. Novel targeted agents have promise both as single agents, and in combination with chemotherapy. However, further work is needed to identify therapeutic targets and to develop active agents with a view to introducing them into standard clinical practice.